DIM does not produce an acute felt effect like a stimulant or anxiolytic. Subjective reports cluster around delayed (days-to-weeks) downstream effects of altered estrogen physiology:

Reported positive effects (cyclic women, peri/postmenopause, AAS users with high E2):

• Reduced PMS, breast tenderness, cyclical mood swings (week 2-4)
• Reduced cyclical bloating
• Subjective improvement in hormonal acne (3-8 weeks)
• For AAS users on cycle: reduced gyno-prodrome symptoms, reduced water retention

Reported neutral or absent effect in healthy young men:

• Most don't notice anything at 100 mg/day
• Some report mild fatigue, "flat" mood, or reduced libido at 200+ mg

Reported negative effects (high-dose, chronic):

• Reduced libido and erection quality (consistent with AR antagonism)
• Fatigue, "low-T-feel"
• Headache (especially first week)
• Orange/yellow urine tint (harmless but jarring)
• GI upset, nausea (especially fasted, non-fat-coadministered doses)

Time course: AhR-mediated CYP induction is established in days; downstream estrogen-metabolite ratio shift takes 2-4 weeks to stabilize. Subjective claims of next-day effects are unlikely to be mechanistic.

• Pharmacodynamic tolerance: Not well characterized. CYP1A induction is durable while exposure continues; some down-regulation on discontinuation but no documented "rebound" pattern.
• Receptor tolerance: AhR pathway has feedback regulation (AhR repressor protein, ARR), so chronic high-dose DIM may produce some attenuation of the CYP1A1 induction signal. Clinically, the 2:16 ratio shift persists across multi-month dosing in trials.
• Recommended cycling: No firm requirement. Pragmatic protocols: 3 months on / 1 month off for women; continuous use during AAS cycles for men managing E2; symptom-driven discontinuation otherwise.
• Reset protocol: Discontinuation → CYP1A induction wanes over ~2-4 weeks. Estrogen metabolite ratio normalizes over 4-8 weeks.

Synergistic with

• calcium-d-glucarate (CDG): Strong pharmacological complementarity. CDG inhibits β-glucuronidase, preventing reabsorption of glucuronidated estrogens in the gut — so phase II conjugation isn't undone enterohepatically. DIM shifts upstream hydroxylation; CDG enforces downstream excretion. The textbook DIM + CDG stack is widely used for estrogen-clearance support; 100-150 mg DIM + 500-1000 mg CDG/day is typical. Not a Dylan stack.
• sulforaphane: Both cruciferous-derived but mechanistically distinct (sulforaphane = NRF2 activator → phase II detox enzymes; DIM = AhR → CYP1A induction). Some practitioners stack them for "complete cruciferous coverage." For most users including Dylan, sulforaphane alone covers the NRF2 / glutathione / phase II benefits with cleaner mechanism and no anti-androgen risk — cross-link to sulforaphane.md.
• vitamin B6, B12, folate, methylation co-factors: Estrogen detoxification requires methylation (COMT methylates 2-OH-E1 to 2-methoxy-E1, the cleanest exit). Methyl-donor support reduces "estrogen detox stall."
• magnesium, zinc: Standard hormonal-balance adjuncts; no specific DIM synergy beyond background nutrition.

Avoid stacking with

• Aromatase inhibitors (anastrozole, letrozole, exemestane) at clinical doses: DIM is not an AI but stacking with prescription AIs risks over-suppression of estradiol in AAS users. Pick one lever, dial in, then add if needed — don't blanket-suppress.
• Tamoxifen: Thomson 2017 RCT showed DIM reduces active tamoxifen metabolite (endoxifen) levels via CYP induction. Avoid in tamoxifen patients without oncologist sign-off.
• Other strong CYP1A2 substrates taken at therapeutic dose (theophylline, clozapine, olanzapine, tizanidine): CYP1A2 induction by DIM accelerates clearance and may drop these drugs sub-therapeutic.
• Hormonal contraceptives: Theoretical reduced efficacy. If on the pill / patch / ring, layer barrier or non-hormonal IUD when starting DIM.

Neutral / safe co-administration

• Creatine, omega-3, vitamin D, magnesium, NAC, glycine, taurine — no known interactions.
• Standard nootropics (citicoline, alpha-GPC, rhodiola, ashwagandha) — no known interactions.

DIM's metabolic profile:

• Induces CYP1A1, CYP1A2, CYP1B1 (the AhR-target genes) — established in human liver slice studies and in vivo.
• Induces CYP3A4 and MDR1 (P-glycoprotein) via human PXR activation — DIM is a human PXR ligand. Important for drug interactions beyond the CYP1A axis.

Clinically significant interactions:

1. Tamoxifen — reduced endoxifen levels. Thomson 2017 demonstrated this directly. Avoid combo without oncology guidance.
2. Hormonal contraceptives — possibly reduced efficacy via CYP1A2 + CYP3A4 induction increasing ethinyl estradiol clearance. Layer non-hormonal contraception.
3. CYP1A2 substrates — theophylline, caffeine (high doses), clozapine, olanzapine, fluvoxamine, tizanidine, propranolol (partial), zolmitriptan, melatonin (partial). DIM accelerates clearance; effect size unquantified in humans but mechanistically established.
4. CYP3A4 substrates — wide swath of drugs (many statins, some calcium channel blockers, midazolam, cyclosporine, certain antiretrovirals, some chemo agents). Pragmatically, anyone on multiple Rx drugs should not add DIM without pharmacist review.
5. P-glycoprotein substrates — digoxin, dabigatran, some anticancer agents. DIM may reduce systemic exposure via MDR1 induction.
6. Anticoagulants (warfarin): Theoretical interaction via CYP induction; monitor INR if combined.
7. Caffeine: Heavy caffeine users (>400 mg/day) may notice reduced caffeine effect — DIM accelerates caffeine clearance via CYP1A2 induction. Not Dylan-relevant (caffeine-baseline = zero) but worth flagging in stack design.

• *CYP1A2 polymorphism (rs762551, 1F): Fast vs slow metabolizer status modulates baseline 2-OH-E1 production. *1F/*1F (fast metabolizers) may need less DIM to shift the 2:16 ratio meaningfully; *1A/*1A (slow) may need more. 23andMe raw data interpretable via Promethease.
• COMT Val/Val vs Met/Met: COMT methylates 2-OH-E1 → 2-methoxy-E1 (the cleanest exit). Met/Met (slow COMT) may accumulate catechol estrogens (2-OH, 4-OH) without efficient methylation — theoretically, adding DIM without methylation support raises 2-OH-E1 in a slow-COMT background with unclear safety. Hedge with B-vitamin / methyl-donor support.
• CYP1B1 polymorphism: Modulates 4-hydroxylation pathway (the genotoxic estrogen metabolite branch). DIM's CYP1B1 induction is real; in carriers with high-activity CYP1B1 variants, DIM could theoretically increase 4-OH-E1 along with 2-OH-E1. Under-characterized in vivo.
• AR CAG repeat length: Shorter CAG = higher AR sensitivity; DIM's anti-androgen effects may be more pronounced in short-CAG carriers (≤21 repeats).
• Practical takeaway for Dylan (23andMe pending June 2026): None of these PGx hits change the verdict for him — no estrogen issue means no indication — but they're worth re-reading once data lands if the question reopens later (e.g., on an AAS cycle in his late 20s).

Sourcing-difficulty rating: easy. Widely available OTC, FDA GRAS, no Rx required.

For Dylan: not stocking. No use case in his archetype.

Baseline (before starting, if starting)

• Total testosterone + free testosterone + SHBG — DIM raises SHBG (Thomson 2017); free T may drop even if total T stable
• Estradiol (sensitive LC-MS/MS assay, not standard immunoassay) — only meaningful if abnormal at baseline
• Urinary 2-OH:16α-OHE1 ratio (e.g., DUTCH Complete or estronex) — direct measure of the targeted mechanism
• TSH, fT4 — DIM modulates thyroid-relevant CYPs; watch in thyroid patients
• LFTs (ALT/AST) — baseline before any chronic supplementation
• CBC, lipid panel — general background

During use

• Months 2-3: repeat E2 (if monitoring E2 management), total T, free T, SHBG. If T drops or free T falls disproportionate to SHBG rise → consider reducing dose or stopping.
• Subjective: libido VAS, erection quality (men), cycle regularity / breast tenderness (women), mood, energy daily for 2 months.
• Urine color check first 2 weeks — adapt to expected orange tint.
• Months 3-6: repeat urinary 2:16 ratio if that was the primary indication.

Post-discontinuation

• E2 and T at 4-8 weeks off — confirm reversal if anti-androgenic effects suspected.